옵션 체인은 다양한 행사가격과 만기일에 대한 Kinsale Cap Gr의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Kinsale Cap Gr에 대한 시장 심리를 평가합니다..

Kinsale Cap Gr (NYSE:KNSL) 주식, 옵션 체인

KINSALE CAPITAL GROUP INC

Kinsale Cap Gr

Kinsale Capital Gr

Kinsale Capital Group

Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.

Tesla Inc. TSLA

Large Cap

News

Movers

Trading Ideas

BF/B

CVNA

Fomento Economico Mexicano S.A.B. De C.V.

KNSL

SOFI

TCOM

TSLA

YUMC

이들 9개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 카바나(NYSE:CVNA)의 주가는 20.93% 급락했다. 공매도 업체인 힌덴버그 리서치의 비판적인 보고서는 Carvana의 회복을 &#34;신기루&#34;로 묘사하면서 약세 정서를 강화했다.

테슬라, 소파이 및 주류 주식이 지난주 최악의 성과를 보인 9개 대형주 중 일부 (12월 30일-1월 3일)

Kinsale Capital Group Inc

Blackboxstocks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBX#NASDAQ">BLBX</a>), ("Blackbox" or the "Company"), announces that its merger target REalloys Inc. ("REA" or "REalloys"), has signed a joint Memorandum of Understanding ("MOU") with the Saskatchewan Research Council ("SRC") to begin working together to advance REA's initiative of commercial production of high-performance rare earth magnet materials. REA's planned production starts in Q2, with targeted expansion to 500 metric tonnes ("mt") per year of magnet materials in 2026, and 1,000 mt by 2028.&nbsp;&nbsp; This is a major milestone to achieve the objective of a secure &amp; resilient North American magnet materials &amp; magnets supply chain focused on demand from U.S. Protected Markets (includes: National Defense Stockpiles ("NDS"), Defense Industrial Base ("DIB"), Nuclear Industrial Base ("NIB"), Robotics, Electric Aviation, Critical Infrastructure industries, and for U.S. Partner Countries with Defense Treaties, Alliances &amp; Agreements).
By combining REA's mid-stream production capabilities in heavy rare earth dysprosium-terbium ("DyTb") metals with SRC's mid-stream production capabilities in light rare earth neodymium-praseodymium ("NdPr") metals, high performance magnet materials can now be made in North America, at REA's Euclid, Ohio facility, to supply U.S. Protected Markets.

BLBX

Blackboxstocks' Merger Target REalloys Signs Joint MOU With Saskatchewan Research Council To Begin Working Together To Advance REA's Initiative Of Commercial Production Of High-Performance Rare Earth Magnet Materials

Evercore ISI Group analyst Steve Sakwa maintains Cousins Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUZ#NYSE">CUZ</a>) with a In-Line and raises the price target from $30 to $31.

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on Cousins Props, Raises Price Target to $31

Skillful Craftsman Education Technology Limited ("Skillful Craftsman" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDTK#NASDAQ">EDTK</a>), a company focused on advancing technological innovation in education through the digital transformation of educational institutions, today announced new business initiatives designed to propel the Company's growth.

EDTK

Skillful Craftsman Education Technology Launches New Business Initiatives To Drive Growth And Advance Digital Transformation In Education

Management

BBWI

Bath & Body Works Appoints Daniel Heaf As CEO

Evercore ISI Group maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a In-Line and raises the price target from $13 to $15.

Evercore ISI Group Maintains In-Line on CNH Industrial, Raises Price Target to $15

The Board of Directors of MVB Financial Corp. ("MVBF" or "MVB Financial") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVBF#NASDAQ">MVBF</a>) today announced the authorization of a stock repurchase program of up to $10 million of MVB's common stock.
MVB intends to begin repurchasing stock in May 2025, and the stock repurchase program will expire upon the expenditure of $10 million, when terminated or otherwise completed. Purchases may be made in open-market transactions, in block transactions on or off an exchange, in privately negotiated transactions or by other means as determined by MVB's management and in accordance with the regulations of the Securities and Exchange Commission. The timing of purchases and the number of shares repurchased under the stock repurchase program will depend on a variety of factors including price, trading volume, market conditions and corporate and regulatory requirements.

Buybacks

MVBF

MVB Financial Corp. Announces The Authorization Of A Stock Repurchase Program Of Up To $10M Of Common Stock

Paramount Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGRE#NYSE">PGRE</a>) ("Paramount" or the "Company") announced today that its Board of Directors has initiated a review and evaluation of strategic alternatives to maximize shareholder value. The announcement follows a successful first quarter marked by strong leasing activity.

PGRE

Paramount Group Announces Strategic Alternatives Review To Maximize Shareholder Value

Lifeward Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025.

LFWD

Lifeward Appoints Mark Grant As President And CEO, Effective June 2, 2025

-- First ever clinical data supporting safety and efficacy of Prime Editing in humans --
-- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --
-- Rapid engraftment observed in both neutrophils and platelets --
-- Encouraging safety profile; no serious adverse events related to PM359 --
-- Initiating efforts to explore continued clinical development opportunities for PM359 external to Prime Medicine --
CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in Chronic Granulomatous Disease (CGD). Preliminary results from the first patient demonstrated that PM359 was well-tolerated, showed rapid engraftment and restored NADPH oxidase activity to well above the threshold for clinical benefit, as measured by the dihydrorhodamine (DHR) assay.
CGD is a rare inherited disease that leads to recurrent, debilitating and often life-threatening infections. It is caused by mutations in genes, including&nbsp;NCF1, that encode proteins that form the NADPH oxidase complex, an enzyme that kills bacteria and fungi to control infection. PM359, an ex vivo Prime Edited autologous hematopoietic stem cell (HSC) product for the treatment of p47phox CGD and the first Prime Editor generated therapy to be administered in humans, is designed to correct the delGT mutation in NCF1, the most prevalent disease-causing mutation in the p47phox variant of CGD, thereby addressing its underlying pathophysiology. Prime Medicine estimates that CGD causative mutations occur in between one in 100,000 and one in 200,000 births in the United States, with approximately 25 percent of patients presenting with the p47phox form of the disease.

Biotech

General

PRME

Prime Medicine Announces Initial Data From First Patient Dosed In Phase 1/2 Trial Finds Single Dose Of PM359 Led To 58% 'DHR Positivity' By Day 15 And 66% By Day 30, Well Above Levels Believed To Be Potentially Curative

Hong Kong leading logistics solutions provider New Century Logistics (BVI) Limited (hereinafter referred to as "New Century") today announced the formal signing of a Memorandum of Understanding ("MOU") with Silk Way Airlines Limited (hereinafter referred to as "Silkway"), a well-known air cargo airline in Hong Kong. Both parties will explore innovative solutions in the international air freight logistics sector based on resource sharing and complementary strengths, aiming to enhance global supply chain efficiency for their clients.
Stronger collaboration
According to the MOU, New Century and Silkway will conduct in-depth cooperation in the following directions:
<ul>
<li>Joint development of international air freight logistics solutions: integrating New Century's global logistics network with Silkway's air cargo resources to provide end-to-end efficient transportation services for cross-border trading enterprises.</li>
<li>Market intelligence and logistics best practices sharing: optimize route planning, cost control and risk management capabilities through data exchange and experience sharing.</li>
<li>Collaborative marketing and brand promotion: Joint promotion of services offered by both parties to expand business coverage in Asia Pacific, Europe and emerging markets.</li>
<li>Customer experience upgrade: build a seamless logistics service system, improve the transparency of cargo tracking and delivery timeliness.</li>
</ul>

NCEW

New Century Logistics Signs MOU With Silk Way Airlines To Explore Innovative Solutions In International Air Freight Logistics Sector

Wells Fargo analyst Praneeth Satish maintains Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Overweight and raises the price target from $69 to $71.

Wells Fargo Maintains Overweight on Nextracker, Raises Price Target to $71

FRSX

Trading Halt: Halt status updated at 8:35:00 AM ET: Quotation Resumption: News and Resumption Times

Evercore ISI Group analyst David Raso maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Outperform and lowers the price target from $451 to $419.

Evercore ISI Group Maintains Outperform on Cummins, Lowers Price Target to $419

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology --
-- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
-- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of Directors, named Executive Chair --
-- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points --
CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced a strategic restructuring, including the deprioritization of its Chronic Granulomatous Disease (CGD) programs, as well as a cost and workforce reduction to focus on its liver franchise and programs funded through external partnerships.
Prime Medicine is currently advancing in vivo programs to cure two of the largest genetic liver diseases, Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD), with initial clinical data from both programs expected in 2027. Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. In addition, Prime Medicine will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster its financial resources.
Also today, Prime Medicine announced that Keith Gottesdiener, M.D., has decided to step down as Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Allan Reine, M.D., Prime Medicine's Chief Financial Officer (CFO), has been named CEO and member of the Board of Directors and Jeff Marrazzo, member of the Company's Board of Directors, has been named Executive Chair.

Prime Medicine Implementing Cost Cutting Measures To Significantly Reduce Cash Needs In Advance Of Key Data Inflection Points; Allan Reine, CFO, To Succeed Keith Gottesdiener, As CEO; Jeff Marrazzo, Member Of The Board Of Directors, Named Executive Chair

Patrick Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) ("Patrick" or the "Company"), a leading component solutions provider for the Outdoor Enthusiast and Housing markets, announced that Jake Petkovich will rejoin Patrick as President – Marine, succeeding Rick Reyenger, effective May 19, 2025. Mr. Reyenger will remain with the Company and move to a strategic advisory role to support continuity and ensure a smooth and seamless transition across the Company's Marine businesses.

PATK

Patrick Industries Says Jake Petkovich To Rejoin As President – Marine, Succeeding Rick Reyenger, Effective May 19, 2025

Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) sees Q2 sales of $181.487 million-$194.441 million.

Guidance

Niu Tech expects Q2 2025 Revenue between RMB 1.317B and RMB 1.411B, YoY increase of 40% to 50%.

The renewal from a key client demonstrates strong loyalty, while a new major deal reflects continued growth momentum heading into FY2026.
BEIJING, May 19, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTSS#NASDAQ">DTSS</a>) ("Datasea" or the "Company"), a Nevada-based technology company specializing in acoustic high-tech products and 5G+AI multimodal digital solutions, today announced that its subsidiaries have signed two new service contracts totaling up to $100 million for the provision of 5G-AI multimodal digital services over a 12-month period. The customers include long-term partner Qingdao Ruizhi Yixing Information Technology Co., Ltd. ("Qingdao Ruizhi Yixing") and a new key client, Qingdao Dong'an Information Technology Co., Ltd.
Under the terms of the agreements, Datasea will deliver customized 5G-AI digital services, including data Top-up solutions and AI-powered communication tools, to both Qingdao Ruizhi Yixing and Qingdao Dong'an. Each contract is valued up to $50 million, representing a strong vote of recognition and confidence in the performance and value of Datasea's 5G-AI solutions.

DTSS

Datasea Subsidiaries Sign Two New Service Contracts Totalling Up To $100M For Provision Of 5G-AI Multimodal Digital Services Over 12-Month Period

TransDigm Group and Servotronics Announce ~$110M Definitive Merger Agreement For Servotronics To Become Wholly Owned Subsidiary Of TransDigm

Evercore ISI Group analyst David Raso maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a In-Line and lowers the price target from $375 to $373.

Evercore ISI Group Maintains In-Line on Caterpillar, Lowers Price Target to $373

Evercore ISI Group analyst Michael Binetti maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $65 to $70.

Comments

Kinsale Cap Gr

Kinsale Cap Gr (KNSL) 옵션

Loading...

뉴스

파트너 / 기고자

벤징가 글로벌